Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole

Phyllis M Salzman,1 Arash Raoufinia,2 Susan Legacy,3 Pedro Such,4 Anna Eramo5 1Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, 2Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Salzman PM, Raoufinia A, Legacy S, Such P, Eramo A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	long-acting injectable aripiprazole plasma concentrations dosing schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ca5b79ce43c04b4b963ea261d0ea7795
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca5b79ce43c04b4b963ea261d0ea7795
record_format	dspace
spelling	oai:doaj.org-article:ca5b79ce43c04b4b963ea261d0ea77952021-12-02T11:17:56ZPlasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole1178-2021https://doaj.org/article/ca5b79ce43c04b4b963ea261d0ea77952017-04-01T00:00:00Zhttps://www.dovepress.com/plasma-concentrations-and-dosing-of-2-long-acting-injectable-formulati-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Phyllis M Salzman,1 Arash Raoufinia,2 Susan Legacy,3 Pedro Such,4 Anna Eramo5 1Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, 2Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, 3US Medical Affairs, Neuroscience, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA; 4Medical Affairs Psychiatry, H. Lundbeck A/S, Valby, Denmark; 5Global Clinical Development, CNS, Lundbeck LLC, Deerfield, IL, USA Abstract: Maintaining therapeutic plasma concentrations of an antipsychotic agent is essential in preventing relapse of symptoms in schizophrenia. Long-acting injectable (LAI) formulations provide extended exposure to antipsychotic therapy and have been useful in addressing treatment nonadherence. Aripiprazole is an atypical antipsychotic used in the treatment of schizophrenia and is available in 2 chemically different (aripiprazole monohydrate and aripiprazole lauroxil [AL]) and pharmaceutically different LAI formulations (aripiprazole once-monthly 400 mg [AOM 400] and AL). The pharmaceutical difference is that AL, unlike AOM 400, is a prodrug that requires additional metabolic steps to form the active drug aripiprazole. We present data demonstrating that aripiprazole plasma concentrations are similar for AOM 400 and the 882 mg dose of AL when administered once every 4 weeks and that both provide similar therapeutic plasma concentrations of aripiprazole when compared with therapeutic oral doses. Keywords: long-acting injectable, aripiprazole, plasma concentrations, dosing, schizophreniaSalzman PMRaoufinia ALegacy SSuch PEramo ADove Medical Pressarticlelong-acting injectablearipiprazoleplasma concentrationsdosingschizophreniaNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 1125-1129 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	long-acting injectable aripiprazole plasma concentrations dosing schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	long-acting injectable aripiprazole plasma concentrations dosing schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Salzman PM Raoufinia A Legacy S Such P Eramo A Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
description	Phyllis M Salzman,1 Arash Raoufinia,2 Susan Legacy,3 Pedro Such,4 Anna Eramo5 1Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, 2Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, 3US Medical Affairs, Neuroscience, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA; 4Medical Affairs Psychiatry, H. Lundbeck A/S, Valby, Denmark; 5Global Clinical Development, CNS, Lundbeck LLC, Deerfield, IL, USA Abstract: Maintaining therapeutic plasma concentrations of an antipsychotic agent is essential in preventing relapse of symptoms in schizophrenia. Long-acting injectable (LAI) formulations provide extended exposure to antipsychotic therapy and have been useful in addressing treatment nonadherence. Aripiprazole is an atypical antipsychotic used in the treatment of schizophrenia and is available in 2 chemically different (aripiprazole monohydrate and aripiprazole lauroxil [AL]) and pharmaceutically different LAI formulations (aripiprazole once-monthly 400 mg [AOM 400] and AL). The pharmaceutical difference is that AL, unlike AOM 400, is a prodrug that requires additional metabolic steps to form the active drug aripiprazole. We present data demonstrating that aripiprazole plasma concentrations are similar for AOM 400 and the 882 mg dose of AL when administered once every 4 weeks and that both provide similar therapeutic plasma concentrations of aripiprazole when compared with therapeutic oral doses. Keywords: long-acting injectable, aripiprazole, plasma concentrations, dosing, schizophrenia
format	article
author	Salzman PM Raoufinia A Legacy S Such P Eramo A
author_facet	Salzman PM Raoufinia A Legacy S Such P Eramo A
author_sort	Salzman PM
title	Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
title_short	Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
title_full	Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
title_fullStr	Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
title_full_unstemmed	Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
title_sort	plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/ca5b79ce43c04b4b963ea261d0ea7795
work_keys_str_mv	AT salzmanpm plasmaconcentrationsanddosingof2longactinginjectableformulationsofaripiprazole AT raoufiniaa plasmaconcentrationsanddosingof2longactinginjectableformulationsofaripiprazole AT legacys plasmaconcentrationsanddosingof2longactinginjectableformulationsofaripiprazole AT suchp plasmaconcentrationsanddosingof2longactinginjectableformulationsofaripiprazole AT eramoa plasmaconcentrationsanddosingof2longactinginjectableformulationsofaripiprazole
_version_	1718396075417534464

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole

Ejemplares similares